Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

42.57

Mkt cap

278B

Volume

213K

High

43.31

P/E Ratio

29.63

52-wk high

43.96

Low

42.56

Div yield

N/A

52-wk low

29.20

Alnylam Pharmaceuticals has partnered with Roche to develop and commercialize Zilebesiran, Alnylam's investigational RNAi therapeutic for hypertension treatment. Alnylam will receive an upfront cash payment of $310 million and is eligible for development, regulatory, and sales milestones, potentially valuing the deal at up to $2.8 billion. The companies will share profits and losses equally in the US, and Alnylam will receive royalties on net sales outside the US.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 5:53 am

Hollywood studios propose using AI replicas of actors. Meta Platforms' Threads app sees a decline in engagement. Citigroup, UnitedHealth, Wells Fargo, JPMorgan Chase, and BlackRock deliver strong Q2 earnings. Nokia and Ericsson shares drop after Q2 earnings. Roivant Sciences in talks with Roche for a potential $7B drug deal. WHO labels aspartame as a possible carcinogen. Microsoft and Activision Blizzard consider UK rights divestiture to appease regulators. Nissan plans to invest in Renault's EV unit. Novo Nordisk's weight-loss drug to be launched in Germany.

Portfolio Pulse from Vandana Singh

July 14, 2023 | 2:09 pm

Roivant Sciences Ltd (ROIV), founded by Republican presidential candidate Vivek Ramaswamy, is in talks with Roche Holdings AG (RHHBY) for the potential sale of an experimental drug for stomach diseases. The deal could exceed $7 billion. The drug, RVT-3101, is currently in the final Phase 3 testing stage. Roivant obtained the drug through a deal with Pfizer Inc (PFE), which retains a 25% stake in the subsidiary and holds commercial rights outside the U.S. and Japan.

Portfolio Pulse from Vandana Singh

July 14, 2023 | 12:55 pm

Roivant Sciences is reportedly in discussions to sell its stomach drug to Roche in a deal that could be valued at over $7 billion, according to the Wall Street Journal.

Portfolio Pulse from Charles Gross

July 13, 2023 | 9:53 pm

Roche Holdings AG's Phase 3 OCARINA II trial evaluating Ocrevus as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with multiple sclerosis. The subcutaneous injection was shown to be non-inferior to Ocrevus given by intravenous infusion. The investigational subcutaneous formulation combines Ocrevus with Halozyme Therapeutics Inc's Enhanze drug delivery technology.

Portfolio Pulse from Vandana Singh

July 13, 2023 | 1:22 pm

Roche's OCREVUS, which uses Halozyme's ENHANZE drug delivery technology, has announced positive results from its Phase 3 OCARINA II trial in patients with Multiple Sclerosis.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 6:04 am

Genentech, a member of the Roche Group, has voluntarily withdrawn the U.S. indication of Gavreto, a drug developed in collaboration with Blueprint Medicines. The decision is not due to new safety/efficacy data for Gavreto or product safety/quality issue.

Portfolio Pulse from Charles Gross

June 30, 2023 | 10:26 am

Blue Water Biotech Inc (NASDAQ:BWV) has released encouraging preclinical data for its monkeypox vaccine candidate, developed using its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform. The vaccine candidate has shown potential in neutralizing the vaccinia virus, which is closely related to monkeypox. Meanwhile, Roche Holdings AG's (OTC:RHHBY) cobas MPXV has received FDA Emergency Use Authorization for detecting monkeypox DNA.

Portfolio Pulse from Vandana Singh

June 28, 2023 | 5:51 pm

Roche has received FDA clearance for additional Alzheimer's disease cerebrospinal fluid assays, expanding its diagnostic capabilities.

Portfolio Pulse from Bill Haddad

June 27, 2023 | 1:06 pm

The FDA has granted accelerated approval to Roche's Columvi (glofitamab-gxbm) for the treatment of relapsed or refractory diffuse large B-cell lymphoma and large B-cell lymphoma arising from follicular lymphoma. The approval is based on the phase 1/2 NP30179 study results, which showed durable remission in patients treated with fixed-duration Columvi.

Portfolio Pulse from Vandana Singh

June 16, 2023 | 2:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.